Sign up to access all valuation multiples
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives. Geographically, it operates in UK, North America, Europe, and Asia and Rest of World.
2005
199
LTM Revenue $50.3M
LTM EBITDA $8.2M
$143M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diaceutics has a last 12-month revenue (LTM) of $50.3M and a last 12-month EBITDA of $8.2M.
In the most recent fiscal year, Diaceutics achieved revenue of $43.1M and an EBITDA of $3.7M.
Diaceutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diaceutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $50.3M | XXX | $43.1M | XXX | XXX | XXX |
| Gross Profit | $43.8M | XXX | $37.9M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $8.2M | XXX | $3.7M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $0.5M | XXX | -$3.3M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | $0.7M | XXX | -$2.3M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Diaceutics's stock price is GBP 1 (or $2).
Diaceutics has current market cap of GBP 118M (or $159M), and EV of GBP 107M (or $143M).
See Diaceutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $143M | $159M | XXX | XXX | XXX | XXX | $0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Diaceutics has market cap of $159M and EV of $143M.
Diaceutics's trades at 3.3x EV/Revenue multiple, and 38.5x EV/EBITDA.
Equity research analysts estimate Diaceutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diaceutics has a P/E ratio of 238.7x.
See valuation multiples for Diaceutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $159M | XXX | $159M | XXX | XXX | XXX |
| EV (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.4x | XXX | 38.5x | XXX | XXX | XXX |
| EV/EBIT | 276.6x | XXX | -43.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 238.7x | XXX | -69.5x | XXX | XXX | XXX |
| EV/FCF | -145.5x | XXX | -26.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiaceutics's last 12 month revenue growth is 24%
Diaceutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Diaceutics's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diaceutics's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diaceutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 56% | XXX | 73% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 96% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diaceutics acquired XXX companies to date.
Last acquisition by Diaceutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Diaceutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Diaceutics founded? | Diaceutics was founded in 2005. |
| Where is Diaceutics headquartered? | Diaceutics is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Diaceutics have? | As of today, Diaceutics has 199 employees. |
| Who is the CEO of Diaceutics? | Diaceutics's CEO is Mr. Ryan Keeling. |
| Is Diaceutics publicy listed? | Yes, Diaceutics is a public company listed on LON. |
| What is the stock symbol of Diaceutics? | Diaceutics trades under DXRX ticker. |
| When did Diaceutics go public? | Diaceutics went public in 2019. |
| Who are competitors of Diaceutics? | Similar companies to Diaceutics include e.g. AnteoTech, Proteomics International, Biohit, Genomictree. |
| What is the current market cap of Diaceutics? | Diaceutics's current market cap is $159M |
| What is the current revenue of Diaceutics? | Diaceutics's last 12 months revenue is $50.3M. |
| What is the current revenue growth of Diaceutics? | Diaceutics revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Diaceutics? | Current revenue multiple of Diaceutics is 2.8x. |
| Is Diaceutics profitable? | Yes, Diaceutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diaceutics? | Diaceutics's last 12 months EBITDA is $8.2M. |
| What is Diaceutics's EBITDA margin? | Diaceutics's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Diaceutics? | Current EBITDA multiple of Diaceutics is 17.4x. |
| What is the current FCF of Diaceutics? | Diaceutics's last 12 months FCF is -$1.0M. |
| What is Diaceutics's FCF margin? | Diaceutics's last 12 months FCF margin is -2%. |
| What is the current EV/FCF multiple of Diaceutics? | Current FCF multiple of Diaceutics is -145.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
